Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Immuno-Oncology Firm Neon Launches

by Lisa M. Jarvis
October 5, 2015 | A version of this story appeared in Volume 93, Issue 39

Joining the increasingly crowded immuno-oncology fray, Neon Therapeutics has launched with $55 million in financing from Third Rock Ventures, Clal Biotechnology Industries, and Access Industries. The Cambridge, Mass.-based biotech is developing therapeutic vaccines and T-cell therapies targeting neoantigens, tumor-specific proteins that appear to help cancer cells evade the immune system. Neon will work up both personalized therapies—tuned to a cancer patient’s specific neoantigens—as well as off-the-shelf vaccines and T-cell therapies. Neon’s first drug candidate, NEO-PV-01, is a personalized neoantigen vaccine developed by the Broad Institute and Dana-Farber Cancer Institute.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.